Acute inflammation in healthy people is normally followed by a resolution phase that returns tissue to homeostasis.
Once thought to be a passive event, Professor Charles Serhan at Harvard Medical School discovered that inflammation resolution is a highly regulated process coordinated by Specialized Proresolving Mediators (SPMs), a superfamily of immunoregulatory autacoids that includes the Resolvins. In inflammatory diseases, the resolution process is dysregulated and the immune system can cause massive damage.
Dr. Serhan discovered that treating inflammatory diseases with Resolvins can activate the body's natural resolution programs to resolve unmitigated inflammation without compromising immune function. Resolvin E1 (RvE1), the active moiety in our lead drug candidate TP-317, is one of the most widely investigated SPMs since its discovery 20 years ago. RvE1 has been shown to halt the infiltration of activated immune cells, dampen proinflammatory cytokine responses and initiate efferocytosis and clearance of cellular debris in inflamed tissue, while also promoting the repair of damaged tissue. Taken together, these pro-resolving properties make SPMs such as RvE1 attractive candidates for the treatment of inflammatory disorders.
However, the development of Resolvin therapeutics has been hampered by the fact that endogenous Resolvins are oily, unstable, and difficult to administer as pharmaceutical drugs and generally have weak intellectual property protection as natural materials. Using our proprietary HEALER technology, we unlock the powerful biology of Resolvins to enable their pharmaceutical development. By leveraging innate biology, our approach has prospects for the safe and effective treatment of inflammatory diseases.